Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies.
about
Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activityClinical utility of biomarkers of endothelial activation in sepsis--a systematic reviewEndocan and the respiratory system: a reviewGlobal gene expression profiling of dimethylnitrosamine-induced liver fibrosis: from pathological and biochemical data to microarray analysis.Loss of Endocan tumorigenic properties after alternative splicing of exon 2.Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndromeCharacteristics of serum endocan levels in infection.Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromesEndocan: A new marker for cancer and a target for cancer therapy.Identification of Predictive Early Biomarkers for Sterile-SIRS after Cardiovascular Surgery.Spatial and temporal dynamics of the endothelium.Endocan of the maternal placenta tissue is increased in pre-eclampsiaThe Relationship between Serum Endocan Levels and Depression in Alzheimer's Disease.Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.Lower serum endocan levels are associated with the development of acute lung injury after major traumaPlasma endocan level and prognosis of immunoglobulin A nephropathy.Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma.Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling.Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?Endothelium and regulatory inflammatory mechanisms during organ rejection.Markers for sepsis diagnosis in the forensic setting: state of the art.Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension.Serum Endocan as a Predictive Marker for Decreased Urine Volume in Peritoneal Dialysis Patients.Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan.ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma.Serum endothelial cell specific molecule-1 (endocan) levels in patients with obstructive sleep apnea.Murine glomerular transcriptome links endothelial cell-specific molecule-1 deficiency with susceptibility to diabetic nephropathy.ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells.Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression.Endocan: A Novel Marker of Endothelial Dysfunction in C1-Inhibitor-Deficient Hereditary Angioedema.Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease.Endocan, Obstructive Sleep Apnea, and Vascular Risk.Serum endocan levels in endometrial and ovarian cancers.Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma.Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study.P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease.Effect of Non-Surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A, and Tumor Necrosis Factor-Alpha Levels.Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome.Vitamin D Treatment Effect on Serum Endocan and High-Sensitivity C-Reactive Protein Levels in Renal Transplant Patients.
P2860
Q95988784-CEC23023-1B78-4D41-ADAD-6D0F72AAF786Q95988786-3AD72556-381F-46BF-910A-177E830B68C3Q95988787-1405685A-B9E9-4E70-B362-408EB115811FQ95988788-70D827E2-D1D1-40E9-A4BE-A0F6C2A38405Q95988789-7C4533CE-45AA-4750-8E7E-1C8C15F27787Q95988790-ED3DA4F2-B411-4767-A109-A885E51FF262Q95988791-A414523E-72AE-428B-867E-DCC15CE1DF80Q95988792-17530423-5025-4A54-9BA3-2FF87661D64B
P1343
Q24291764-1DB9203A-70C6-4B04-ACFF-B6B3B7AED06DQ26823450-D9782647-856E-4D25-AED6-E006FC080048Q28069363-585064B6-00B8-4B53-B79E-A6CA6D3E2C1AQ33259183-C6FC7A99-5B94-4E20-8086-AFA482413DF5Q33315465-04D8CC46-A4E2-4DA5-B67B-70D122C941A3Q34012386-FE0ABE65-4DFD-44A9-BB3F-7E5AF603D422Q35500737-7EAF1593-14B8-4828-A938-7FC369A6F099Q35547367-45A93AA6-CB0E-4DD5-A6B1-8DE608FE4E39Q35681482-920896BD-8ACC-42CA-B2A2-007DA2C3003DQ35742583-B67F12C9-7D85-4C7B-B6B7-580AE2A2E6FAQ36126944-EEB3A955-0D37-4F87-BA1F-FBABF3C753C6Q36464599-A9B3A1B2-CC46-42F1-8B13-B375F8A731F7Q36559163-A760B6E2-8E23-496E-AEB5-79476FCFAC41Q36868721-746E71E6-F83C-4B9D-9C35-E3FA44066DBCQ37215391-6E8110AB-E8F0-4509-BFF2-34542A95100CQ37260183-DB5AF3F6-E929-478C-8285-9B95CAE8529CQ37657319-DA150A1F-FB96-4F71-87A1-09549961533CQ37683320-3B1E9A97-FD7D-402A-BE73-C98063352BDBQ37894728-A3E0CDCD-80B8-450B-A01E-4F31E1410121Q38103486-6460478B-F8D4-456A-B2B3-09E9DE4968FBQ38207964-C90E6CCB-25C9-45DE-8719-1DB7738BF805Q38797262-72218CD6-1AD4-475D-AD26-33A945F490B7Q38876082-BFC39E64-D637-4767-831F-B406BA6C69B6Q39431959-0FA3C656-3A7D-4ABE-A7A2-A6790175D044Q39658846-32168D7F-E272-4144-BCEB-EEB3105AB8B0Q40952479-4DDE3BE2-82D6-4FA6-8822-B73E17E99DA6Q42253708-E689BE58-34B5-4B81-971E-48F6B6090C04Q42283730-9E259F6B-ADE2-4D89-84BB-9FB427249EF2Q43202086-AD205453-15D9-456E-A48C-ADCB94E238EAQ47105893-05BDA6E9-7D40-4C0A-955E-1DD9FB8D2F86Q47601818-15AF467C-3BA7-4B8E-9B4E-296C213E29D1Q47928951-B8FD7C88-756B-4E59-8D18-430A18EE3737Q47964690-8D975439-743E-46BC-AF84-57A6EAD3BB53Q47982714-E207FB1A-42E1-4FF5-8E92-0A2EF2DA1863Q49722319-83696566-B421-4C8B-A250-CDC31A30CBCAQ51065264-C2AFB77B-0D02-4120-A635-635B9D67EF52Q51093923-16229031-51CE-4B3C-8B57-3BF8204CE073Q51263015-DF0B8698-43F8-4E1C-BA1D-3D0D34F7F10EQ51275626-39FCB171-6E35-4A9C-B6DC-255FD9CFB45FQ51553969-1994541E-C1D3-4A06-93D1-F84DABD5CC31
P2860
Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Characterization of the secret ...... pecific monoclonal antibodies.
@ast
Characterization of the secret ...... pecific monoclonal antibodies.
@en
type
label
Characterization of the secret ...... pecific monoclonal antibodies.
@ast
Characterization of the secret ...... pecific monoclonal antibodies.
@en
prefLabel
Characterization of the secret ...... pecific monoclonal antibodies.
@ast
Characterization of the secret ...... pecific monoclonal antibodies.
@en
P2093
P356
P1476
Characterization of the secret ...... specific monoclonal antibodies
@en
P2093
A Scherpereel
G Kervoaze
P Bertheau
P304
P356
10.1159/000025758
P577
2000-09-01T00:00:00Z